| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785784 | Cancer Treatment Reviews | 2018 | 6 Pages |
Abstract
Immunotherapy improved OS compared to SOC in mRCC, irrespective of treatment line. In first-line, immunotherapy also increased the ORR compared to sunitinib. A lack of correlation between OS and PFS was confirmed, the latter to be used cautiously for the design and interpretation of trials involving immunotherapy in mRCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Davide Bimbatti, Emanuela Fantinel, Claudia Mosillo, Iolanda Bisogno, Matteo Brunelli, Giampaolo Tortora, Camillo Porta,